Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

BACKGROUND: Lenvatinib (E7080), an oral multi-kinase inhibitor, has inhibitory action on tumor cell proliferation and tumor angiogenesis in preclinical models. We evaluated correlations between pharmacodynamic (PD) biomarkers with patient clinical outcomes in a lenvatinib phase 1 dose-escalation stu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Koyama, Noriyuki, Saito, Kenichi, Nishioka, Yuki, Yusa, Wataru, Yamamoto, Noboru, Yamada, Yasuhide, Nokihara, Hiroshi, Koizumi, Fumiaki, Nishio, Kazuto, Tamura, Tomohide
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2014
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4223557/
https://ncbi.nlm.nih.gov/pubmed/25047123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-530
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia